Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

RDN for CKD and Uncontrolled Hypertension Trial

16 november 2026 bijgewerkt door: Beijing Anzhen Hospital

Effect and Safety of Renal Denervation in Uncontrolled Hypertension and Chronic Kidney Disease: A Randomized, Sham-control, Blinded, Clinical Trial

Prospective, Multi-Center, Randomized, Parallel-Controlled, Uptake clinical trial to evaluate the efficacy and safety of renal denervation in patients with uncontrolled hypertension and chronic kidney disease.

Studie Overzicht

Gedetailleerde beschrijving

This Prospective, Multi-Center, Randomized, parallel-controlled uptake clinical trial aims to evaluate the efficacy and safety for renal denervation in patients with uncontrolled hypertension and chronic kidney disease, and to provide clinical evidence supporting the expansion of indications.

Studietype

Ingrijpend

Inschrijving (Geschat)

248

Fase

  • Niet toepasbaar

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studiecontact

Studie Contact Back-up

Studie Locaties

      • Beijing, China, 101118
        • Werving
        • Beijing Anzhen Hospital
        • Contact:

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

18 jaar tot 65 jaar (Volwassen, Oudere volwassene)

Accepteert gezonde vrijwilligers

Nee

Geslachten die in aanmerking komen voor studie

Allemaal

Beschrijving

Inclusion Criteria:

  1. Male or female, aged 18 to 65 years, inclusive, at the time of consent;
  2. Hypertensive subjects who have been taking 2 types of standardized antihypertensive drugs continuously and stably for at least 4 weeks, with office systolic blood pressure still ≥150 mmHg and <180 mmHg, and 24-hour ambulatory mean systolic blood pressure (24h SBP) ≥135 mmHg and <170 mmHg; or who have been taking ≥3 types of standardized antihypertensive drugs continuously and stably for at least 4 weeks, with office systolic blood pressure ≥140 mmHg and <180 mmHg, and 24h SBP ≥130 mmHg and <170 mmHg;
  3. Estimated glomerular filtration rate (eGFR) ≥20 mL/min/1.73m² and <60 mL/min/1.73m²;
  4. The presence or absence of accessory renal arteries is acceptable;
  5. The subject or his/her legal representative fully understands the content of the informed consent form for this trial and voluntarily signs the written informed consent form.

Exclusion Criteria:

  1. Pregnant or breastfeeding, or planning pregnancy during the study.
  2. Renal artery anatomy unsuitable for ablation (e.g., ≥50% stenosis, renal artery aneurysm, malformation, renal artery diameter <3 mm, or treatable segment length <20 mm).
  3. Subjects with a solitary kidney, prior renal transplantation, or requiring dialysis.
  4. Prior renal artery intervention or prior renal denervation.
  5. Other secondary hypertension not related to kidney disease (such as primary aldosteronism, pheochromocytoma/paraganglioma, Cushing's syndrome, thyroid disease, aortic coarctation, monogenic hypertension, renovascular hypertension, etc.).
  6. Allergic to contrast agents.
  7. Major surgery or trauma within 1 month before enrollment; acute coronary syndrome within 6 months; or planned surgery or cardiovascular interventional therapy within the next 6 months.
  8. Orthostatic hypotension.
  9. Type 1 diabetes mellitus.
  10. Primary pulmonary arterial hypertension.
  11. History of bleeding diathesis and haematological disorders or coagulopathy
  12. History of thromboembolic event within 6 months.
  13. History of stroke or transient ischemic attack (TIA) within 6 months.
  14. Severe peripheral arterial disease or unstable abdominal aortic aneurysm.
  15. Severe valvular heart disease or anticipated need for surgical valve replacement during the study period.
  16. NYHA Class III/IV heart failure at screening or hospitalization for exacerbation of chronic heart failure within the past six months.
  17. History of ventricular fibrillation, polymorphic ventricular tachycardia within six months, or prior implantation of an implantable cardioverter-defibrillator (ICD) or pacemaker.
  18. Acute kidney injury (AKI) within 4 weeks before enrollment or acute kidney disease ,AKI: ≥50% increase in serum creatinine within 7 days, or absolute increase ≥0.3 mg/dL (≥26.5 μmol/L) within 48 hours, or oliguria (<0.5 mL·kg-¹·h-¹ for ≥6 hours).
  19. Severe hepatic dysfunction.
  20. Concomitant severe diseases that may interfere with study participation or affect survival, such as malignancy or AIDS.
  21. Known drug or alcohol dependence, difficulty understanding the study protocol, inability or unwillingness to comply with follow-up requirements.
  22. Current or planned participation in other clinical trials of drugs or medical devices (post-marketing registry studies permitted).
  23. Acute or severe systemic infection.
  24. Other conditions deemed unsuitable for participation by the investigator.

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Behandeling
  • Toewijzing: Gerandomiseerd
  • Interventioneel model: Parallelle opdracht
  • Masker: Enkel

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Experimenteel: Renal Denervation (RDN)

Participants receive percutaneous renal sympathetic denervation under digital subtraction angiography (DSA) guidance using a ultra-guiding radiofrequency denervation catheter. All participants receive a standardized antihypertensive regimen for ≥4 weeks before the procedure and thereafter per protocol. Follow-up visits occur at 7 days or before discharge, and at 1, 3, 6, 12 months.

DSA-guided percutaneous renal sympathetic denervation using a RF renal denervation system

Andere namen:
  • Renale denervatie
Sham-vergelijker: Parallel control with sham operation

Participants undergo a sham procedure: femoral artery puncture and selective renal angiography under DSA guidance are performed. The RF generator is connected to a dummy load, and activation sounds are emitted, but no energy is delivered. Participants remain on the procedure table for at least 35 minutes before sheath removal. Background standardized antihypertensive therapy is provided for ≥4 weeks pre-procedure and continued per protocol. Follow-up visits occur at 7 days or before discharge, and at 1, 3, 6, and 12 months.

Sham procedure including femoral artery puncture and selective renal angiography; the radiofrequency generator is connected to a dummy load and produces activation sounds, but no energy is delivered. Minimum table time before sheath removal is 35 minutes.

Andere namen:
  • Renale angiografie

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Change from Baseline in 24-hour Ambulatory Systolic Blood Pressure at Month 6 (ABPM)
Tijdsspanne: Baseline to Month 6 post-procedure

24-hour mean systolic BP measured by validated ambulatory BP monitoring; change is Month 6 minus Baseline

Baseline to Month 6 post-procedure

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Change from Baseline in 24-hour Ambulatory Diastolic Blood Pressure at Month 6 (ABPM)
Tijdsspanne: Baseline to Month 6 post-procedure

24-hour mean systolic BP measured by validated ambulatory BP monitoring

Baseline to Month 6 post-procedure
Change from Baseline in Office Blood Pressure (including both systolic and diastolic BP)
Tijdsspanne: Baseline to Months 1, 3, 6 and 12 post-procedure

measured by validated office blood pressure monitoring

Baseline to Months 1, 3, 6 and 12 post-procedure
Change from Baseline in 24-hour Ambulatory Systolic Blood Pressure (including both systolic and diastolic BP)
Tijdsspanne: Baseline to Months 1, 3, and 12 post-procedure

24-hour mean systolic BP measured by validated ambulatory BP monitoring

Baseline to Months 1, 3, and 12 post-procedure
Change from Baseline in Daytime and Nighttime Ambulatory Systolic Blood Pressure (ABPM)
Tijdsspanne: Baseline to Months 1, 3, 6, and 12 post-procedure

24-hour mean systolic BP measured in Daytime and Nighttime by validated ambulatory BP monitoring

Baseline to Months 1, 3, 6, and 12 post-procedure
Percentage of Participants with 24-hour Ambulatory Systolic BP <130 mmHg
Tijdsspanne: Months 1, 3, 6, and 12 post-procedure

24-hour mean systolic BP measured by validated ambulatory BP monitoring

Months 1, 3, 6, and 12 post-procedure
Percentage of subjects with office systolic BP within the target ranges (<140 mmHg and <130 mmHg)
Tijdsspanne: Months 6 and 12 post-procedure

measured by validated office blood pressure monitoring

Months 6 and 12 post-procedure
Responder Rate: ≥5 mmHg Reduction in office Systolic BP
Tijdsspanne: Months 6 and 12 post-procedure

Proportion of participants with a reduction ≥5 mmHg from baseline in office BP

Months 6 and 12 post-procedure
Change from Baseline in Antihypertensive Medication Use
Tijdsspanne: Months 1, 3, 6 and 12 post-procedure

Change in the number of concurrently prescribed antihypertensive agents

Months 1, 3, 6 and 12 post-procedure
Change from Baseline in serum creatinine levels
Tijdsspanne: Months 1, 3, 6 and 12 post-procedure

Change in postoperative serum creatinine levels relative to baseline

Months 1, 3, 6 and 12 post-procedure
Changes from Baseline in glomerular filtration rate
Tijdsspanne: Months 1, 3, 6 and 12 post-procedure

Changes in glomerular filtration rate relative to baseline

Months 1, 3, 6 and 12 post-procedure
Changes from Baseline in the urine microalbumin-to-creatinine ratio
Tijdsspanne: Months 1, 3, 6 and 12 post-procedure

Changes in the urine microalbumin-to-creatinine ratio relative to baseline

Months 1, 3, 6 and 12 post-procedure
Change from Baseline in Heart Rate (by ECG)
Tijdsspanne: Months 1, 3, 6 and 12 post-procedure

Resting heart rate measured by standard 12-lead ECG; change is Follow-up minus Baseline

Months 1, 3, 6 and 12 post-procedure
Change from Baseline in left ventricular ejection fraction (LVEF) (by Echocardiography)
Tijdsspanne: Months 12 post-procedure

by Echocardiography

Months 12 post-procedure
Change from Baseline in left ventricular mass index
Tijdsspanne: Months 12 post-procedure

by Echocardiography

Months 12 post-procedure

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Werkelijk)

8 december 2025

Primaire voltooiing (Geschat)

31 oktober 2027

Studie voltooiing (Geschat)

30 april 2028

Studieregistratiedata

Eerst ingediend

26 oktober 2026

Eerst ingediend dat voldeed aan de QC-criteria

16 november 2026

Eerst geplaatst (Werkelijk)

18 november 2026

Updates van studierecords

Laatste update geplaatst (Werkelijk)

18 november 2026

Laatste update ingediend die voldeed aan QC-criteria

16 november 2026

Laatst geverifieerd

1 november 2026

Meer informatie

Termen gerelateerd aan deze studie

Plan Individuele Deelnemersgegevens (IPD)

Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?

NEE

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Nee

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren